Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

Expert Opinion on Investigational Drugs

Volumn 23, Issue 6, 2014, Pages 875-882

  Lamos, Elizabeth M ^a   Younk, Lisa M ^a   Davis, Stephen N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Empagliflozin; Glycemic control; Sodium glucose co transporter 2 inhibitor; Type 1 diabetes mellitus

Indexed keywords

DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; PLACEBO; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL (TOPIC); DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RENAL PROTECTION; SODIUM ABSORPTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ULTRAFILTRATION; WAIST CIRCUMFERENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 1; METABOLISM; PHASE 2 CLINICAL TRIAL (TOPIC);

ANIMALS; BENZHYDRYL COMPOUNDS; CLINICAL TRIALS, PHASE II AS TOPIC; DIABETES MELLITUS, TYPE 1; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84900812229     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.909407     Document Type: Article

References (39)

1. The top 10 causes of death [Internet]. 2013. Available from: http://who.int/mediacentre/factsheets/fs310/en/
2. Hypoglycemia in the diabetes control and complications trial. The diabetes control and complications trial research group. Diabetes 1997;46(2):271-86
3. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The epidemiology of diabetes interventions and complications (EDIC) study. JAMA 2003;22;290(16): 2159-67
4. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26(6):1902-12
5. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353(25):2643-53
6. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95(1):34-42
7. Scheepers A, Joost HG, Schurmann A. The glucose transporter families SGLT and GLUT: Molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr 2004;28(5):364-71
8. Guyton AC, Hall JE. editor. Textbook of medical physiology. 11th edition. Elsevier Inc, Philadelphia, PA; 2006
9. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14(1):5-14
10. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract 2008;14(6):782-90
11. Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl 2007;35(106):S27-35
12. Adachi T, Yasuda K, Okamoto Y, et al. T-1095, a renal na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism 2000;49(8):990-5
13. Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-Affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007;320(1):323-30
14. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57(6):1723-9
15. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971;28(1):101-9
16. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951;30(2):125-9
17. Kamran M, Peterson RG, Dominguez JH. Overexpression of GLUT2 gene in renal proximal tubules of diabetic zucker rats. J Am Soc Nephrol 1997;8(6):943-8
18. Dominguez JH, Song B, Maianu L, et al. Gene expression of epithelial glucose transporters: the role of diabetes mellitus. J Am Soc Nephrol 1994;5(5 Suppl 1):S29-36
19. Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol 2012;74:351-75
20. Macha S, Jungnik A, Hohl K, et al. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers. Int J Clin Pharmacol Ther 2013;51(11):873-9
21. Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther 2013;35(1):A33-42
22. Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther 2013;4(2):331-45
23. Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013;15(7):613-21
24. Macha S, Mattheus M, Halabi A, et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 2014;Mar;16(3):215-22
25. Ferrannini E, Seman L, Seewaldt-Becker E, et al. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013;15(8):721-8
26. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51(5):1145-9
27. Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and zucker fatty rats. Eur J Pharmacol 2009;609(1-3):148-54
28. Luippold G, Klein T, Mark M, Grempler R. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab 2012;14(7):601-7
29. Henry RR, Rosenstock J, Chalamandaris A, et al. Exploring the potential of dapagliflozin in type 1 diabetes: phase 2a pilot study. 2013:Presentation Abstract 70-LB
30. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014. [Epub ahead of print]
31. Cherney DZ, Perkins BA, Soleymanlou N, et al. The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes. Circulation 2014;4;129(5):587-97
32. Vallon V, Blantz RC, Thomson S. Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol 2003;14(2):530-7
33. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014;13:28
34. Safety and efficacy of empagliflozin (BI 10773) in type 1 diabetes mellitus patients with or without renal hyperfiltration [Internet]; 2013 updated 10 July 2013. Available from: http://clinicaltrials.gov/show/NCT01392560
35. Macha S, Rose P, Mattheus M, et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab 2013. [Epub ahead of print]
36. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)-A randomized placebo-controlled trial. Am Heart J 2013;166(2):217-223.e11
37. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2013. [Epub ahead of print]
38. Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab 2013;15(12):1154-60
39. Empagliflozin add-on to insulin in type 1 diabetes mellitus over 28 days [Internet]; 2013 updated 10 December 2013. Available from: http:// clinicaltrials. gov/ct2/show/NCT01969747